Callos Andrew 4
4 · CYTOKINETICS INC · Filed Mar 5, 2026
Insider Transaction Report
Form 4
CYTOKINETICS INCCYTK
Callos Andrew
EVP, Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2026-03-05$39.13/sh+11,000$430,430→ 76,440 total - Sale
Common Stock
2026-03-05$61.87/sh−15,000$928,050→ 61,440 total - Sale
Common Stock
2026-03-05$61.88/sh−11,000$680,680→ 50,440 total - Exercise/Conversion
Common Stock
2026-03-05$23.26/sh+15,000$348,900→ 65,440 total - Exercise/Conversion
Non-Qualified Stock Option (Right to Buy)
2026-03-05−11,000→ 24,403 totalExercise: $39.13From: 2023-04-06Exp: 2033-03-06→ Common Stock (11,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option (Right to Buy)
[F1]2026-03-05−15,000→ 69,000 totalExercise: $23.26From: 2022-03-31Exp: 2031-03-31→ Common Stock (15,000 underlying)
Footnotes (1)
- [F1]Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
Signature
/s/ John O. Faurescu, attorney-in-fact for Mr. Callos|2026-03-05